Corvus Pharmaceuticals, Inc.
$12.50
-$0.05 (-0.40%)
$12.25Day Range$12.60
Key Statistics
Market Cap
$1.06B
Shares Outstanding
84.1M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Mar 23, 2016
Round Lot
100
Locale
US
Trading Data
Day Open
$12.53
Day High
$12.60
Day Low
$12.25
Volume
435.6K
VWAP
$12.49
Prev Close
$12.55
Transactions
--
Acc. Volume
--
About Corvus Pharmaceuticals, Inc.
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.
PHARMACEUTICAL PREPARATIONSSIC 283437 employees901 GATEWAY BLVD, THIRD FLOOR, SOUTH SAN FRANCISCO, CA, 94080(650) 900-4520IPO Mar 23, 2016US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001626971
- Composite FIGI
- BBG009F0TGH8
- Share Class FIGI
- BBG009F0TGJ6
- Ticker Root
- CRVS
- SIC Code
- 2834
About Corvus Pharmaceuticals, Inc. (CRVS) Stock
Corvus Pharmaceuticals, Inc. (CRVS) closed the 2026-09-18 session at $12.50, down 0.40% versus the previous close (-0.05). The stock opened at $12.53 and traded between $12.25 and $12.60 during that session. Session trading volume was 436K shares. The volume-weighted average price (VWAP) is $12.49.
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.
Corvus Pharmaceuticals, Inc. has a market capitalization of $1.06 billion. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. CRVS is listed on the XNAS exchange. The company employs approximately 37 people. Corvus Pharmaceuticals, Inc. is headquartered in SOUTH SAN FRANCISCO, CA. The recorded listing date is 2016-03-23.
On this page you can find market CRVS stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.